Skip to main content

Advertisement

SpringerLink
Log in

President’s address: Treatment of tamoxifen-refractory breast cancer — approach by animal models

  • Published:
Breast Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Nomura Y, Tashiro H, Shinozuka K,et al: Changes of steroid hormone receptor content by chemotherapy and/or endocrine therapy in advanced breast cancer.Cancer 55: 546–551, 1985.

    Article  PubMed  CAS  Google Scholar 

  2. Ottaviano YL, Issa JP, Parl FF,et al: Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells.Cancer Res 54: 2552–2555, 1994.

    PubMed  CAS  Google Scholar 

  3. Watts CKW, Handel ML, King RJB,et al: Oestrogen receptor gene structure and function in breast cancer.J Steroid Biochem Mol Biol 41: 529–536, 1992.

    Article  PubMed  CAS  Google Scholar 

  4. Karni PS, Kulkarni S, Liu X-P,et al: Estrogen receptor mutations in tamoxifen-resistant breast cancer.Cancer Res 54: 349–353, 1994.

    Google Scholar 

  5. Wolf DM, Jordan VC: The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain.Breast Cancer Res Treat 31: 129–138, 1994.

    Article  PubMed  CAS  Google Scholar 

  6. Levenson AS, Catherino WH, Jordan VC: Estrogenic activity is increased for an antiestogen by natural mutation of the estogen receptor.J Steroid Biochem Mol Biol 60: 261–268, 1997.

    Article  PubMed  CAS  Google Scholar 

  7. Levenson AS, Jordan VC: The key to the antiestrogenic mechanism of raloxifen is amino acid 351 (Aspartate) in the estrogen receptor.Cancer Res 58: 1872–1875, 1998.

    PubMed  CAS  Google Scholar 

  8. Speirs V, Malone C, Walton DS,et al: Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients.Cancer Res 59: 5421–5424, 1999.

    PubMed  CAS  Google Scholar 

  9. Paech K, Webb P, Kuiper GGJM,et al: Differential ligand activation of estrogen receptors ER α and ER β at AP1 sites.Science 277: 1508–1510, 1997.

    Article  PubMed  CAS  Google Scholar 

  10. Fujimoto N, Katzenellenbogen BS: Alteration in the agonist/antagonist balance of antiestrogens by activation of protein kinase A signaling pathways in breast cancer cells: Antiestrogen selectivity and promoter dependence.Mol Endocrinol 8: 296–304, 1994.

    Article  PubMed  CAS  Google Scholar 

  11. Webb P, Lopez GN, Uht RM,et al: Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens.Mol Endocrinol 9: 443–446, 1995.

    Article  PubMed  CAS  Google Scholar 

  12. Jordan VC: Designer estrogens.Scientific American 279: 60–67, 1998.

    Article  PubMed  CAS  Google Scholar 

  13. Knabbe C, Kopp A, Hilgers W,et al: Regulation and role of TGF beta production in breast cancer.Ann NY Acad Sci 784: 263–276, 1996.

    Article  PubMed  CAS  Google Scholar 

  14. MacCallun J, Keen JC, Bartlett JMS,et al: Changes in expression of transforming growth factor beta mRNA isoforms in patients undergoing tamoxifen therapy.Br J Cancer 74: 474–478, 1996.

    Google Scholar 

  15. Herman ME, Katzenellenbogen BS: Response-specific antiestrogen resistance in a newly characterized MCF-7 human breast cancer cell line resulting from long-term exposure to trans-hydroxytamoxifen.J Steroid Biochem Mol Biol 59: 121–134, 1996.

    Article  PubMed  CAS  Google Scholar 

  16. Arteaga CL, Koli KM, Dugger TC,et al: Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-beta.J Natl Cancer Inst 91: 46–53, 1999.

    Article  PubMed  CAS  Google Scholar 

  17. Kopp A, Jonat W, Schmahl M,et al: Transforming growth factor beta 2 (TGF-beta 2) levels in plasma of patients with metastatic breast cancer treated with tamoxifen.Cancer Res 55: 4512–4515, 1995.

    PubMed  CAS  Google Scholar 

  18. Gasparini G, Toi M, Miceli R,et al: Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.Cancer J Sci Am 5: 101–111, 1999.

    PubMed  CAS  Google Scholar 

  19. Ruohola JK, Valve EM, Karkkainen MJ,et al: Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells.Mol Cell Endocrinol 149: 29–40, 1999.

    Article  PubMed  CAS  Google Scholar 

  20. DiGiovanna MP: Clinical significance of HER-2/neu over-expression: Part 1. In: Rosenberg SA, ed. Principles and Practice of Oncology Updates (Vol 13, No 9). PA: Lippincott Williams & Wilkins, Philadelphia, 1999.

    Google Scholar 

  21. Tour AD, Liu S, Edgerton S,et al: Activation (Tyrosine Phosphorylation) of ErbB-2 (HER-2/neu): A study of incidence and correlation with outcome in breast cancer.J Clin Oncol 18: 3230–3239, 2000.

    Google Scholar 

  22. Johnston SRD, Haynes BP, Sacks NPM,et al: Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration.Lancet 342: 1521–1522, 1993.

    Article  PubMed  CAS  Google Scholar 

  23. Osborne CK, Coronado EB, Wiebe VJ,et al: Acquired tamoxifen resistance: Correlation with reduced tumor levels of tamoxifen and isomerization of trans-4-hydrox-ytamoxifen.J Natl Cancer Inst 83: 1477–1482, 1991.

    Article  PubMed  CAS  Google Scholar 

  24. Wieve VJ, Osborne CK, McGuire WL,et al: Identification of estrogenic tamoxifen metabolite (s) in tamoxifen-resistant human breast tumors.J Clin Oncol 10: 990–994, 1992.

    Google Scholar 

  25. Wolf DM, Langan-Fahey SM, Parker CJ,et al: Investigation on the mechanism of tamoxifen-stimulated breast tumor growth using nonisomerizable analogs of tamoxifen and metabolites.J Natl Cancer Inst 85: 805–812, 1993.

    Article  Google Scholar 

  26. Jordan VC, Fritz NF, Langan-Fahey S,et al: Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent.J Natl Cancer Inst 83: 1488–1491, 1991.

    Article  PubMed  CAS  Google Scholar 

  27. Lum SS, Woltering EA, Fletcher WS,et al: Changes in serum estrogen levels in women during tamoxifen therapy.Am J Surg 173: 399–402, 1997.

    Article  PubMed  CAS  Google Scholar 

  28. Harada N: Aromatase and intracrinology of estrogen in hormone- dependent tumors.Oncology 57 (Suppl 2): 7–16, 1999.

    Article  PubMed  CAS  Google Scholar 

  29. Iino Y, Ogawa T, Yoshida M,et al: Effects of OK-432 (Picibanil) on estrogen receptor levels and tamoxifen treatment in 7,12-dimethylbenz [a] anthracene-induced rat mammary cancers.Oncology 47: 185–190, 1990.

    Article  PubMed  CAS  Google Scholar 

  30. Iino Y, Yoshida M, Tago T,et al: Effects of sequential and combined immuno-endocrine therapies using OK-432 (picibanil) and tamoxifen on the growth of 7,12-dimethylbenz [a] anthracene-induced rat mammary carcinoma.Jpn J Clin Oncol 21: 35–38, 1991.

    PubMed  CAS  Google Scholar 

  31. Iino Y, Wolf DM, Langan-Fahey SM,et al: Reversible control of estradiol-stimulated growth of MCF-7 tumors by tamoxifen in the athymic mouse.Br J Cancer 64:1019–1024.

  32. Takei H, Lee ES, Cisneros A,et al: Effects of angiogenesis inhibitor TNP-470 on tamoxifen-stimulated MCF-7 breast tumors in nude mice.Cancer Lett 155: 129–135, 2000.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Japanese Breast Cancer Society, Japan

    Yuichi Iino

Authors
  1. Yuichi Iino
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Reprint requests to Yuichi lino, Department of Emergency and Critical Care Medicine, Gunma University Faculty of Medicine, 3-39-15 Showamachi, Maebashi, Gunma 371–8511, Japan.

About this article

Cite this article

Iino, Y. President’s address: Treatment of tamoxifen-refractory breast cancer — approach by animal models. Breast Cancer 8, 262–264 (2001). https://doi.org/10.1007/BF02967522

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02967522

Key words

Search

Navigation